A phase II study to assess the hemodynamic effects of istaroxime, a novel lusinotropic agent, in patients hospitalized with worsening heart failure and a reduced left ventricular systolic function
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Istaroxime (Primary)
- Indications Acute heart failure; Heart failure; Left ventricular dysfunction
- Focus Therapeutic Use
- Acronyms HORIZON-HF
- 01 Apr 2008 Results have been presented (ACC 2008).
- 17 Mar 2008 New trial record.